VERA
Vera Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
32.50
▲ 1.24 (3.97%)
MARKET · —
Price
Open
31.39
Prev close
31.26
Day high
32.97
Day low
31.03
Volume
1.28M
Market cap
$2.33B
P/E (TTM)
—
52W range
21.15 – 56.05
Trailing performance
Returnvs SPY
1W
+2.04%
+3.4%
1M
-11.21%
-14.9%
3M
-6.04%
-9.1%
6M
-22.71%
-33.8%
YTD
-36.27%
-48.6%
1Y
+46.04%
+26.0%
3Y
+87.65%
+13.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.33B
Enterprise value$1.90B
Revenue (TTM)—
Gross profit—
EBITDA$-415.22M
Net income$-401.90M
EPS (TTM)$-5.87
Free cash flow$-212.95M
Total cash$499.16M
Total debt$76.91M
Book value / share$5.67
Shares outstanding72.06M
Float52.39M
Short % of float24.14%
Dividend yield—
Beta (5Y)0.95
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.31
PEG ratio—
Price / sales—
Price / book5.70
EV / revenue—
EV / EBITDA-4.58
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-91.75%
Return on assets-46.76%
Debt / equity18.86
Current ratio10.92
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$299.62M | -$152.15M | -$95.99M | -$89.06M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$299.62M | -$152.15M | -$95.99M | -$89.06M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.59 | -1.52 | +4.4% |
| Dec 2025 | -1.27 | -1.39 | -9.7% |
| Sep 2025 | -1.18 | -1.26 | -7.1% |
| Jun 2025 | -0.62 | -1.20 | -94.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.59 | 7 | $0 | 0.0% |
| Next quarter | -1.57 | 7 | $17.49M | 0.0% |
| Current year | -6.32 | 8 | $25.53M | 0.0% |
| Next year | -4.41 | 8 | $234.89M | +819.9% |
Analyst targets & ownership
Mean target$77.14
High target$100.00
Low target$34.00
Implied upside137.36%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy1 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders0.95%
Held by institutions117.96%
Institutions holding313
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-42.30K
Net selling
Buy transactions
6
180.64K shares
Sell transactions
14
222.94K shares
Net transactions
+20
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
687.48K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 3, 26 | BOMAN NANCY LEE M.D., PH.D. Officer |
STOCK | 44.99K | $0 | Direct |
| Jul 7, 26 | FORDYCE MARSHALL Chief Executive Officer |
CONVERSION | 46.25K | $133.98K | Direct |
| Jul 7, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 46.25K | $1.96M | Direct |
| Jul 7, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 46.25K | $1.96M | Direct |
| Jun 23, 26 | FORDYCE MARSHALL Chief Executive Officer |
CONVERSION | 18.50K | $53.59K | Direct |
| Jun 23, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 18.50K | $701.77K | Direct |
| Jun 23, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 18.50K | $701.77K | Direct |
| May 12, 26 | FORDYCE MARSHALL Chief Executive Officer |
CONVERSION | 18.50K | $53.59K | Direct |
| May 12, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 18.50K | $679.75K | Direct |
| May 12, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 18.50K | $679.75K | Direct |
| Apr 14, 26 | FORDYCE MARSHALL Chief Executive Officer |
SELL | 22.95K | $1.01M | Direct |
| Mar 23, 26 | WRIGHT-MITCHELL CATHERINE JANE Officer |
STOCK | 42.40K | $0 | Direct |
| Mar 13, 26 | YOUNG JOSEPH R Officer |
CONVERSION | 10.00K | $39.40K | Direct |
| Feb 23, 26 | TURNER WILLIAM DONALD Officer |
SELL | 2.19K | $91.82K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRENNER ROBERT |
Officer | 50.95K | Sale |
CARTER JASON S |
Officer | 49.14K | Sale |
ENRIGHT PATRICK G. |
Director | 5.40M | Purchase |
FORDYCE MARSHALL |
Chief Executive Officer | 457.27K | Conversion of Exercise of derivative security |
GRANT SEAN |
Chief Financial Officer | 119.18K | Sale |
JOHNSON DAVID LEE |
Chief Operating Officer | 45.73K | Sale |
SEIDENBERG BETH C |
Director | 135.56K | Sale |
SKELTON LAURENCE MATTHEW |
Officer | 64.22K | Sale |
TURNER WILLIAM DONALD |
Officer | 45.31K | Sale |
YOUNG JOSEPH R |
Officer | 75.75K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
31.21
+4.13% from price
SMA 20
31.78
+1.54% from price
SMA 50
36.15
-10.71% from price
SMA 100
36.67
-11.37% from price
SMA 200
39.06
-17.37% from price
EMA 12
31.82
+2.13% from price
EMA 26
33.12
-1.86% from price
EMA 50
34.66
-6.23% from price
RSI (14)
46.2
Neutral
MACD (12,26,9)
-1.30
Hist 0.33
ATR (14)
1.82
5.65% of price
Realised vol 30D
57.5%
Annualised
Bollinger upper
34.54
20, 2σ
Bollinger lower
29.03
20, 2σ
50 / 200 cross
Death
36.15 vs 39.06
Trend bias
Below 200
-17.37%
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
57.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.1%
Peak to trough
Max drawdown 5Y
-84.9%
Peak to trough
ATR 14
1.82
5.65% of price
Beta (reported)
0.95
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.75
Call-heavy session
Put / call open interest
0.30
Positioning, not flow
Max pain
35.00
+8.4% from spot
ATM implied vol
103.5%
Nearest strike to spot
Skew (10% OTM)
+11.9%
Puts bid over calls
Call volume
106
Contracts, this expiry
Put volume
80
Contracts, this expiry
Heaviest call OI
35.00
4.80K contracts
Heaviest put OI
30.00
1.34K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $43, Maintains Neutral Rating
MT Newswires · 11d ago
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · 12d ago
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 15d ago
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
MarketBeat · 42d ago
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?
Simply Wall St. · 43d ago
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval
Simply Wall St. · 43d ago
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run
Simply Wall St. · 43d ago
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
GlobeNewswire · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.